Advertisement

Topics

Amgen, Allergan submit BLA to FDA for biosimilar candidate to Herceptin

05:38 EDT 2 Aug 2017 | Pharmaceutical Business Review

Amgen and Allergan have submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for ABP 980, a biosimilar candidate to Herceptin (trastuzumab).

Original Article: Amgen, Allergan submit BLA to FDA for biosimilar candidate to Herceptin

NEXT ARTICLE

More From BioPortfolio on "Amgen, Allergan submit BLA to FDA for biosimilar candidate to Herceptin"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...